By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    physical health
    5 Ways Playing Games Can Improve Neural and Physical Health
    September 9, 2022
    Reasons For Hair Loss and Its Treatment
    Reasons For Hair Loss and Its Treatment
    February 16, 2022
    healthcare organization
    5 Actionable Strategies For Healthcare Organizations
    August 15, 2022
    Latest News
    Biohazard Cleanup: The Importance of Proper Disposal and Containment
    December 2, 2023
    Medicare Helps Seniors, and People with Disabilities & ESRD
    November 27, 2023
    The Link Between Allergies and Sinusitis & Strategies for Relief
    November 27, 2023
    What Health Complications Can a Sunburn Cause?
    November 22, 2023
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Medical Complications and Medical Negligence: What’s the Difference?
    September 17, 2012
    Patience Is a Virtue
    September 22, 2014
    The Three Cs of Physician Reputation Management
    May 19, 2016
    Latest News
    Automation in Pharmacovigilance: A Double-Edged Sword
    November 15, 2023
    What Does Science Say About Modern Health Practices?
    November 12, 2023
    Harnessing the Power of Email Marketing in Healthcare
    October 26, 2023
    10 Proven Strategies to Level Up Your Health Business
    October 25, 2023
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Immunotherapy Trains the Immune System to Attack Cancer Cells
Share
Sign In
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Have an existing account? Sign In
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > News > Immunotherapy Trains the Immune System to Attack Cancer Cells
NewsSpecialties

Immunotherapy Trains the Immune System to Attack Cancer Cells

HerinaAyot
Last updated: 2012/06/06 at 2:32 PM
HerinaAyot
Share
4 Min Read
SHARE

Immunotherapy is the new black when it comes to treating Cancer, raising hope in conquering this age old illness. Treating infectious disease using the body’s own defenses operates under the premise that the body is able to retain memory to guard against disease.

Immunotherapy is the new black when it comes to treating Cancer, raising hope in conquering this age old illness. Treating infectious disease using the body’s own defenses operates under the premise that the body is able to retain memory to guard against disease. Cancer immunotherapy operates under a similar premise.

The Wall Street Journal recently published an article highlighting two drugs Bristol-Myers Squibb presented at the American Society of Clinical Oncology (ASCO) last weekend in Chicago.  The presentation came on the heels of last year’s regulatory approval for Yervoy, a drug that employs the immune system to treat advanced Melanoma. Researchers were impressed with its ability to provide long term survival in more than 20% of patients.  The stock peaked at just over $34.00 at today’s open, but has since declined.

Also mentioned in the WSJ were pharma giants, Roche, Merck, and GlaxoSmithKline as pursuers of immunotherapies. But neglected were smaller emerging companies with big ideas in the same field.

Advaxis [ADXS], the 2012 winner of Best Therapeutic Vaccine in the VIE awards, is a development stage biotechnology company with the intent to develop safe and effective immunotherapies for cancer and infectious diseases. These immunotherapies are based on a platform technology under exclusive license from the University of Pennsylvania that utilize live, attenuated Listeria monocytogenes bio-engineered to secrete antigen/adjuvant fusion proteins.

Advaxis’ lead construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3, locally advanced cervical cancer, recurrent/refractory cervical cancer (India), and head & neckcancer. Over 15 distinct constructs are in various stages of development, developed directly by the company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. The stock has fluctuated over the last 3 months, peaking at $0.14 in March just after Best Therapeutic Vaccine win before settling at around $0.10 in recent weeks.

Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies. In collaboration with the National Cancer Institute, Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed, including a Phase III study, demonstrating evidence of safety and efficacy for the treatment of indolent follicular non-Hodgkin’s lymphoma.

In mid-May, Biovest announced it will file for market approval in the European Union for BiovaxID®. EMA approval would establish BiovaxID as the first cancer vaccine available in Europe for lymphoma patients.

The stock peaked mid February at $0.75 after being covered in several media outlets including Drug Discovery New, OneMedResarch and Fox News website which predicted the advance of Cancer vaccines in 2012 including BiovaxID® Lymphoma Vaccine. It has since been slowly declining and has hovered in the $0.45 range in recent weeks.

Stay tuned for an in-depth look into the advantages and disadvantages of big pharma’s new immunotherapy toys, and why a certain failure in Europe may be an omen. We’ll look at how the disruptive technologies in our wheelhouse stack up to the companies that big pharma has committed to.

 

TAGGED: cancer, pharmaceuticals

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
HerinaAyot June 6, 2012 June 6, 2012
Share This Article
Facebook Twitter Copy Link Print
Share
Previous Article Happy Birthday “Silent Spring”
Next Article Image Sorry Works! Helping Healthcare Handle Crises

Stay Connected

1.5k Followers Like
4.5k Followers Follow
2.8k Followers Pin
136k Subscribers Subscribe

Latest News

weight loss
The Key Steps For Affective Weight Loss And Improving Health
Weight Loss Wellness December 6, 2023
Empowering Wellness: HBOT for Home Use Demystified
Empowering Wellness: HBOT for Home Use Demystified
Wellness December 5, 2023
Invasive Dentistry
Precision And Comfort: The Role Of Lasers In Minimally Invasive Dentistry
Dental health Specialties December 4, 2023
sublingual immunotherapy
Sublingual Immunotherapy: A Safe and Effective Alternative to Allergy Shots
Allergy Specialties December 2, 2023

You Might also Like

Invasive Dentistry
Dental healthSpecialties

Precision And Comfort: The Role Of Lasers In Minimally Invasive Dentistry

December 4, 2023
sublingual immunotherapy
AllergySpecialties

Sublingual Immunotherapy: A Safe and Effective Alternative to Allergy Shots

December 2, 2023
allergies and sinusitis
Health

The Link Between Allergies and Sinusitis & Strategies for Relief

November 27, 2023
Sunburned
Health

What Health Complications Can a Sunburn Cause?

November 22, 2023
Subscribe

Subscribe to our newsletter to get our newest articles instantly!

Follow US
© 2008-2023 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Lost your password?